Keyphrases
HER2-positive
100%
Advanced Breast Cancer
100%
Everolimus
100%
Hormone Receptor-positive
100%
Alpelisib
100%
PIK3CA mutation
100%
Clinical Benefit Rate
57%
Objective Response Rate
28%
ESR1 mutation
28%
Endocrine Treatment
28%
Cyclin-dependent Kinase 4 (CDK4)
28%
PIK3CA
14%
Stable Disease
14%
Clinically Significant
14%
Non-associated
14%
Treatment Combination
14%
Best Medical Treatment
14%
Systemic Treatment
14%
Molecular Profiling
14%
Median Progression-free Survival
14%
Progression-free Survival
14%
GATA3
14%
TP53 mutation
14%
Treatment Sequence
14%
MTOR Inhibitor
14%
Cohort Analysis
14%
Real-life Cohort
14%
Medicine and Dentistry
Breast Cancer
100%
Hormone Receptor
100%
Everolimus
100%
Alpelisib
100%
Cohort Analysis
28%
Hormone Therapy
28%
Progression Free Survival
28%
Disease
14%
Protein P53
14%
Systemic Therapy
14%
Transcription Factor GATA 3
14%
Molecular Profiling
14%
Mammalian Target of Rapamycin Inhibitor
14%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Hormone Receptor
100%
Everolimus
100%
Alpelisib
100%
Progression Free Survival
28%
Cohort Study
14%
Disease
14%
Protein P53
14%
Systemic Treatment
14%
Mammalian Target of Rapamycin Inhibitor
14%
Transcription Factor GATA 3
14%